Canertinib dihydrochloride
CAS No. 289499-45-2
Canertinib dihydrochloride ( Canertinib;CI-1033 dihydrochloride;PD-183805 dihydrochloride;CI1033 dihydrochloride )
Catalog No. M13886 CAS No. 289499-45-2
A potent, irreversible, orally available pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 7.5 nM and 9.0 nM in autophosphorylation assay.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 29 | In Stock |
|
10MG | 43 | In Stock |
|
50MG | 61 | In Stock |
|
100MG | Get Quote | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCanertinib dihydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, irreversible, orally available pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 7.5 nM and 9.0 nM in autophosphorylation assay.
-
DescriptionA potent, irreversible, orally available pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 7.5 nM and 9.0 nM in autophosphorylation assay; displays no activity to PDGFR, FGFR, InsR, PKC, and CDK1/2/4; suppresses heregulin-stimulated tyrosine phosphorylation of erbB2, erbB3 and erbB4 with IC50 of 5, 14 and 10 nM, respectively, also inhibits expression of pp62c-fos in response to heregulin; shows high in vivo activity against A431 xenografts.Lung Cancer Discontinued
-
SynonymsCanertinib;CI-1033 dihydrochloride;PD-183805 dihydrochloride;CI1033 dihydrochloride
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR;HER2/ErbB2
-
Research AreaCancer
-
IndicationLung Cancer
Chemical Information
-
CAS Number289499-45-2
-
Formula Weight558.86
-
Molecular FormulaC24H27Cl3FN5O3
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4.Cl.Cl
-
Chemical Name2-Propenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-, hydrochloride (1:2)
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Smaill JB, et al. J Med Chem. 2000 Apr 6;43(7):1380-97.
2. Erlichman C, et al. Cancer Res. 2001 Jan 15;61(2):739-48.
3. Nyati MK, et al. Clin Cancer Res. 2004 Jan 15;10(2):691-700.
4. Slichenmyer WJ, et al. Semin Oncol. 2001 Oct;28(5 Suppl 16):80-5.
2. Erlichman C, et al. Cancer Res. 2001 Jan 15;61(2):739-48.
3. Nyati MK, et al. Clin Cancer Res. 2004 Jan 15;10(2):691-700.
4. Slichenmyer WJ, et al. Semin Oncol. 2001 Oct;28(5 Suppl 16):80-5.
molnova catalog
related products
-
Dacomitinib
Dacomitinib (PF-00299804, PF-299804) is a potent, irreversible, orally active pan-ErbB receptor tyrosine kinase inhibitor with IC50 of 6, 45.7 and 73.7 for EGFR, ERBB2 and ERBB4, respectively.
-
NRC-2694
NRC-2694 is an antagonist of the epidermal growth factor receptor (EGFR). It has anti-cancer and anti-proliferative properties.
-
Dihydroberberine
Dihydroberberine has anti-atherosclerotic anti-inflammatory hypolipidemic and antitumor activities. It inhibits human ether-a-go-go-related gene (hERG) channels and remarkably reduces Hsp90 expression and its interaction with hERG.